Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18 2021 - 8:00AM
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immuno-gene therapies derived from its
Immulytic™ platform, today announced that Philip Astley-Sparke,
Chief Executive Officer of Replimune, will present at the SVB
Leerink 10th Annual Global Healthcare Conference being held
virtually on Wednesday, February 24, 2021 at 8:40 AM ET.
A simultaneous webcast will be available in the Investors
section of Replimune’s website at www.replimune.com. A replay will
be available for approximately 90 days following the
conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded
in 2015 to develop the next generation of oncolytic immune-gene
therapies for the treatment of cancer. Replimune is developing
novel, proprietary therapeutics intended to improve the direct
cancer-killing effects of selective virus replication and the
potency of the immune response to the tumor antigens released.
Replimune’s Immulytic™ platform is designed to maximize systemic
immune activation, in particular to tumor neoantigens, through
robust viral-mediated immunogenic tumor cell killing and the
delivery of optimal combinations of immune-activating proteins to
the tumor and draining lymph nodes. The approach is expected to be
highly synergistic with immune checkpoint blockade and other
approaches to cancer treatment across a broad range of cancers.
Replimune intends to progress these therapies rapidly through
clinical development in combination with other immuno-oncology
products with complementary mechanisms of action as well as in
standalone indications. For more information, please visit
www.replimune.com.
Investor Inquiries Chris BrinzeyWestwicke
Partners339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2023 to Apr 2024